Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers

S. Nagalla, L. Thomson, Y. Oppong, B. Bachman, I. Chervoneva, W. K. Kraft

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC (p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.

Original languageEnglish (US)
Pages (from-to)176-180
Number of pages5
JournalClinical and Translational Science
Volume9
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Thrombin
Healthy Volunteers
Assays
Blood
apixaban
prothrombin complex concentrates

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. / Nagalla, S.; Thomson, L.; Oppong, Y.; Bachman, B.; Chervoneva, I.; Kraft, W. K.

In: Clinical and Translational Science, Vol. 9, No. 3, 01.06.2016, p. 176-180.

Research output: Contribution to journalArticle

Nagalla, S. ; Thomson, L. ; Oppong, Y. ; Bachman, B. ; Chervoneva, I. ; Kraft, W. K. / Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. In: Clinical and Translational Science. 2016 ; Vol. 9, No. 3. pp. 176-180.
@article{d93afa45cf194685866a843355c145da,
title = "Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers",
abstract = "It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76{\%} higher at 30 min postinfusion with 4F-PCC (p = 0.025). The difference declined to 24{\%} at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.",
author = "S. Nagalla and L. Thomson and Y. Oppong and B. Bachman and I. Chervoneva and Kraft, {W. K.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/cts.12398",
language = "English (US)",
volume = "9",
pages = "176--180",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers

AU - Nagalla, S.

AU - Thomson, L.

AU - Oppong, Y.

AU - Bachman, B.

AU - Chervoneva, I.

AU - Kraft, W. K.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC (p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.

AB - It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC (p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.

UR - http://www.scopus.com/inward/record.url?scp=84975045700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975045700&partnerID=8YFLogxK

U2 - 10.1111/cts.12398

DO - 10.1111/cts.12398

M3 - Article

VL - 9

SP - 176

EP - 180

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 3

ER -